Effectiveness of local anticoagulation of the ECMO oxygenator during flow reduction trial in patients on V-A ECMO: a prospective observational cohort study

Effectiveness of local anticoagulation of the ECMO oxygenator during flow reduction trial in patients on V-A ECMO: a prospective observational cohort study - Anticoagulation during flow reduction in V-A ECMO

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON54247

Enrollment

Registered

2023-12-07

Start date

2024-02-19

Completion date

Unknown

Last updated

2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiogenic shock

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: All adult (>18 years old) patients on V-A ECMO with a planned flow reduction trial can be included in this study.

Exclusion criteria

Exclusion criteria: - Patients in whom a heparin bolus has be given due to low APTT just prior to a planned flow reduction trial - Patient with supratherapeutic APTT (>80ms) - Flow reduction trial lasting less than 15 min - No informed consent

Design outcomes

Primary

Measure	Time frame
The main endpoint of the study is the increase in APTT in the ECMO circuit at the end of a flow reduction trial compared to the start of the flow reduction trial	—

Secondary

Measure	Time frame
- The increase in systemic APTT after a flow reduction trial. - The increase in aXa and Inten CT- Heptem CT both in the ECMO circuit and systemic at the end of a flow reduction trial compared to the start of the flow reduction trial	—

Countries

Netherlands

Outcome results